Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/JCP.0000000000000503 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Quetiapine is associated with pancreatitis: A real-world pharmacovigilance study.
J Affect Disord
January 2025
Department of Medicine, University of British Columbia, 2194 Health Sciences Mall, Vancouver, British Columbia V6T 1Z3, Canada. Electronic address:
Quetiapine, an atypical antipsychotic widely prescribed for conditions such as schizophrenia, bipolar disorder, and major depressive disorder, has been associated with a potential risk of pancreatitis. This study aimed to quantify the association between quetiapine use and the occurrence of pancreatitis using data from the FDA Adverse Events Reporting System. Disproportionality analyses were conducted to evaluate the frequency of pancreatitis reports linked to quetiapine compared to other drugs in the FAERS database.
View Article and Find Full Text PDFSexual dysfunctions associated with antipsychotic drug intake: a retrospective analysis of the FDA adverse events reporting system (FAERS).
Naunyn Schmiedebergs Arch Pharmacol
January 2025
University Clinic for Psychiatry and Psychotherapy, Brandenburg Medical School Immanuel Klinik Rüdersdorf, Seebad 82/83, Rüdersdorf bei Berlin, 15562, Rüdersdorf, Germany.
Sexual dysfunctions (SD) are common and debilitating side effects of antipsychotics. The current study analyzes the occurrence of antipsychotic-related SD using data from the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS). FAERS was queried for sexual dysfunction adverse events (encoded by 35 different MedDRA preferred terms) secondary to amisulpride, aripiprazole, chlorprothixene, clozapine, haloperidol, loxapine, olanzapine, pipamperone, quetiapine, risperidone, and ziprasidone from 2000 to 2023.
View Article and Find Full Text PDFAntipsychotic off-label use in the 21st century: An enduring public health concern.
Dialogues Clin Neurosci
December 2025
University Bordeaux, Inserm, Bordeaux Population Health Research Center, Team Pharmacoepidemiology, UMR 1219, Bordeaux, France.
Soon after the introduction of second-generation antipsychotics, antipsychotic off-label use (OLU) progressively became a common prescribing practice. This evolving practice should be regularly monitored considering the growing number of persons exposed to the adverse effects of antipsychotics. The aim of the present review was to synthesise the literature published over the last 15 years on antipsychotic OLU for mental health symptoms.
View Article and Find Full Text PDFTreatment Analysis of Very Early and Early Onset Psychosis in the Youth Inpatient Setting.
HCA Healthc J Med
December 2024
St George's University, Grenada, West Indies.
Background: The United States Food and Drug Administration approved 6 atypical antipsychotics for pediatric treatment of schizophrenia. However, little has been published on the effectiveness of these medications in the acute treatment setting of adolescents with psychosis. Since the clinical uncertainty and poor prognosis proceeding the early onset of schizophrenia has a significant impact on a child's development, there is a critical need for evidence-based data on this population.
View Article and Find Full Text PDFAssociation of statins, gliptins, and antipsychotics with bullous pemphigoid: A case-control study in the Cretan population.
J Dermatol
January 2025
School of Medicine, University of Crete, Heraklion, Greece.
Bullous pemphigoid (BP) is an autoimmune blistering disorder predominantly affecting the elderly. Recently, many studies have shed light on the effect of specific drug intake and comorbidities on the development of BP. The purpose of this study was to investigate the association of specific drug class intake and comorbidities with the development of BP in the Cretan population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!